| 5 mins | 30 mins | Hourly | Daily | Weekly |
|---|---|---|---|---|
| BUY | BUY | BUY | BUY | BUY |
| 5 mins | 30 mins | Hourly | Daily | Weekly | |
|---|---|---|---|---|---|
| MA5 | 1.89▲ | 1.89▼ | 1.90▼ | 1.81▲ | 1.68▲ |
| MA10 | 1.89▲ | 1.90▼ | 1.88▲ | 1.74▲ | 1.60▲ |
| MA20 | 1.89▲ | 1.88▲ | 1.86▲ | 1.68▲ | 1.45▲ |
| MA50 | 1.90▼ | 1.83▲ | 1.79▲ | 1.57▲ | 1.24▲ |
| MA100 | 1.88▲ | 1.78▲ | 1.70▲ | 1.44▲ | 1.22▲ |
| MA200 | 1.85▲ | 1.69▲ | 1.67▲ | 1.34▲ | 1.67▲ |
| 5 mins | 30 mins | Hourly | Daily | Weekly | |
|---|---|---|---|---|---|
| MACD | 0.000▼ | -0.004▼ | 0.000▼ | 0.020▲ | 0.031▲ |
| RSI | 49.457▼ | 55.589▲ | 63.842▲ | 65.207▲ | 63.330▲ |
| STOCH | 59.127 | 34.933 | 64.275 | 76.558 | 77.202 |
| WILL %R | -28.571 | -45.833 | -40.741 | -17.391▲ | -9.412▲ |
| CCI | -73.874 | -53.763 | 30.952 | 142.004▲ | 132.341▲ |
|
Friday, April 17, 2026 02:19 PM
Oral presentation highlights additional data from PROGRESS Phase 2b study of pilavapadin supporting selection of 10mg as optimal dose for Phase 3 development in DPNP New data on spasticity further ...
|
| date | open | high | low | close | volume |
|---|---|---|---|---|---|
| 17/04/26 | 1.86 | 1.95 | 1.855 | 1.87 | 3,132,866 |
| 16/04/26 | 1.86 | 1.89 | 1.81 | 1.84 | 1,962,749 |
| 15/04/26 | 1.75 | 1.86 | 1.74 | 1.86 | 2,129,577 |
| 14/04/26 | 1.70 | 1.7899 | 1.70 | 1.75 | 1,236,515 |
| 13/04/26 | 1.70 | 1.74 | 1.69 | 1.71 | 829,978 |
| 10/04/26 | 1.77 | 1.7999 | 1.695 | 1.72 | 1,350,646 |
| 09/04/26 | 1.65 | 1.84 | 1.65 | 1.76 | 3,938,012 |
| 08/04/26 | 1.65 | 1.70 | 1.62 | 1.67 | 2,302,140 |
| 07/04/26 | 1.59 | 1.645 | 1.55 | 1.60 | 1,883,128 |
| 06/04/26 | 1.59 | 1.6391 | 1.58 | 1.59 | 1,586,979 |
|
|
||||
|
|
||||
|
|